Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunoPrecise Antibodies Ltd. - Common Stock (NQ:IPA)

1.895 +0.415 (+28.04%)
Streaming Delayed Price Updated: 2:23 PM EDT, Jul 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ImmunoPrecise Antibodies Ltd. - Common Stock

< Previous 1 2 3 4 5 Next >
ImmunoPrecise Antibodies Announces Grant of Stock Options
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies Announces Grant of Stock Options
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies Announces Grant of Stock Options
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies and ChemPartner Biologics Announce PolyTope® TATX-03 Antibody Cocktail Manufacturing Collaboration
From IMMUNOPRECISE ANTIBODIES LTD.
Via Business Wire
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Update on its SARS-CoV-2 PolyTope™ Multi-Antibody Cocktail Development Program
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise to Present at the Benchmark Company’s Discovery One-on-One Virtual Video Investor Conference on Thursday December 2, 2021
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA Announces Resignation of Director
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Announces At-The-Market Facility of up to US$50 Million
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration With Pierre Fabre
From ImmunoPrecise Antibodies Ltd
Via Business Wire
ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise’s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13-15, 2021 (Virtual Conference)
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Announces Participation at the H.C. Wainwright 23nd Annual Global Investment Conference on September 13-15, 2021 (Virtual Conference)
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Welcomes Vice President of Client Relations and Vice President of Marketing to its Leadership Team, Accelerating Its Growth and Expansion Plans
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2021
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise's PolyTope™ TATX-03 Antibody Cocktail Potently Neutralizes SARS-CoV-2 Delta Variant in in vitro Pseudovirus Assays
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise to Report Financial Results and Business Highlights for Fiscal Year 2021
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform
From ImmunoPrecise Antibodies
Via Business Wire
Histopathology Preclinical Data from ImmunoPrecise’s Polytope™ Program Confirms Lung Inflammation Reduction
From ImmunoPrecise Antibodies
Via Business Wire
Preclinical Data from ImmunoPrecise’s Drug Pipeline to be Presented During the BIO International Partnering Event
From ImmunoPrecise Antibodies
Via Business Wire
ImmunoPrecise Announces Appointment of Dr. Ilse Roodink to the Role of Chief Scientific Officer and Resignation of Dr. Yasmina Abdiche
From ImmunoPrecise Antibodies
Via Business Wire
ImmunoPrecise Names Dr. Dion Neame to Strategic Advisory Board
From ImmunoPrecise Antibodies
Via Business Wire
ImmunoPrecise Moves SARS-CoV-2 PolyTope™ Cocktail Program’s Path Toward IND Filing
From ImmunoPrecise Antibodies
Via Business Wire
ImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer’s Disease
From ImmunoPrecise Antibodies
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.